[ Price : $8.95]
FDA approves AstraZenecas Imfinzi (durvalumab) in combination with Bacillus Calmette-Guerin (BCG) for treating adults with BCG-nav...[ Price : $8.95]
BrainStorm Cell Therapeutics names former FDA associate commissioner Peter Pitts to its board of directors.[ Price : $8.95]
An FDA advisory committee recommends updating Covid-19 vaccines for the 2026-2027 immunization season to target the currently domi...[ Price : $8.95]
FDA warns Alsip, IL-based GC America about CGMP violations in its production of finished drugs.[ Price : $8.95]
FDA extends its review of an AstraZeneca NDA for camizestrant, an experimental breast cancer therapy, after requesting additional ...[ Price : $8.95]
Corcept Therapeutics plans to resubmit its NDA for relacorilant as a treatment for patients with Cushings syndrome, following addi...[ Price : $8.95]
FDA approves an AbbVie NDA for Decnupaz (pivekimab sunirine-pvzy) and its use in treating adults with blastic plasmacytoid dendrit...[ Price : $8.95]
NSF consultants report on a webinar discussing the best practices in responding to inspection observations in a form FDA-483.